Thanyanan Reungwetwattana

Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste et al. · New England Journal of Medicine · 2017 · 5K citations · Full text

Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC

Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard et al. · New England Journal of Medicine · 2019 · 2.7K citations · Full text

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated <i>EGFR</i>-Mutated Advanced Non–Small-Cell Lung Cancer

Thanyanan Reungwetwattana, Kazuhiko Nakagawa, Byoung Chul Cho et al. · Journal of Clinical Oncology · 2018 · 763 citations · Full text

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

Milind Javle, Maeve A. Lowery, Rachna T. Shroff et al. · Journal of Clinical Oncology · 2017 · 700 citations

Surgical Oncology, Pathology, Phase Ii Study +17

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study

Caicun Zhou, Sang-We Kim, Thanyanan Reungwetwattana et al. · The Lancet Respiratory Medicine · 2019 · 268 citations

Medicine, Randomised Phase 3, Immunology +9